Upgrade to SI Premium - Free Trial

Merck (MRK) Reports EMA Validation of Type II Variation for KEYTRUDA (pembrolizumab) in Combination with Pemetrexed (ALIMTA) and Platinum Chemotherapy

April 23, 2018 4:35 PM
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that following validation by the European ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA Management Comments

Next Articles